Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Pancreatic Neoplasms 10Colorectal Neoplasms 5Stomach Neoplasms 3Rhabdomyosarcoma 3Osteosarcoma 3Biliary Tract Neoplasms 3Sarcoma, Ewing 2Recurrence 2Rectal Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Wilms Tumor 1Small Cell Lung Carcinoma 1Small Bowel Adenocarcinoma 1Sarcoma 1Rhabdoid Tumor 1Rectal Cancer Patients 1Peritoneal Neoplasms 1PDAC - Pancreatic Ductal Adenocarcinoma 1Ovarian Neoplasms 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Nasopharyngeal Carcinoma 1Metastatic Gastric Adenocarcinoma 1Metastatic Adenocarcinoma of the Pancreas 1Malignant Ascites 1Hepatoblastoma 1Gastrointestinal Neoplasms 1Gastroesophageal Junction Adenocarcinoma 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

Paclitaxel 40Carboplatin 34Bevacizumab 29liposomal doxorubicin 20Specimen Handling 18Taxes 17olaparib 16Magnetic Resonance Spectroscopy 16pembrolizumab 15Gemcitabine 15Topotecan 13Immunoglobulin G 11Disulfides 11Biopsy 11mirvetuximab soravtansine 8niraparib 7Nivolumab 7Doxorubicin 7Cyclophosphamide 6Cisplatin 6Drug Therapy 5130-nm albumin-bound paclitaxel 5cemiplimab 4cediranib 4Letrozole 4Injections 4Docetaxel 41-dodecylpyridoxal 4sarilumab 3rucaparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × irinotecan sucrosofate × 1 year × Clear all
NCT07591831 2026-05-18

Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
30 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡